ライフサイエンスコーパス: tumor-associated antigen

1 express influenza hemagglutinin as a unique, tumor-associated antigen.

2 that specifically targets the HER2/neu human tumor-associated antigen.

3 first report of BCG engineered to express a tumor-associated antigen.

4 in cells that overexpress the corresponding tumor-associated antigen.

5 o previously described CTL epitopes for this tumor-associated antigen.

6 on and function of CD8 T cells recognizing a tumor-associated antigen.

7 ptible to cellular immunotherapy targeted to tumor associated antigens.

8 ive imaging of cancer based on expression of tumor associated antigens.

9 cells that recognize MHC class II restricted tumor associated antigens.

10 pecific memory T cells that cross-react with tumor-associated antigens.

11 vely stimulate allogeneic T cells or present tumor-associated antigens.

12 DNA vaccine that may be applicable to other tumor-associated antigens.

13 ic T lymphocyte (CTL) responses against self-tumor-associated antigens.

14 screen the sera of MGUS patients to identify tumor-associated antigens.

15 mmune responses that may be directed against tumor-associated antigens.

16 ed from mucin MUC1 are an important class of tumor-associated antigens.

17 ulate the induction of an immune response to tumor-associated antigens.

18 ion of cytokine effects and/or expression of tumor-associated antigens.

19 d array of naturally processed and presented tumor-associated antigens.

20 gens rather than minor histocompatibility or tumor-associated antigens.

21 sequences from various sources, including 84 tumor-associated antigens.

22 ctive immunization in the absence of defined tumor-associated antigens.

23 ion in order to break tolerance against self tumor-associated antigens.

24 ed eight of nine selected genes as candidate tumor-associated antigens.

25 sed to identify and characterize novel colon tumor-associated antigens.

26 ing cells (APCs) able to take up and present tumor-associated antigens.

27 n obstacle to generating T cell responses to tumor-associated antigens.

28 of monoclonal antibodies (mAbs) recognizing tumor-associated antigens.

29 ptide epitopes that are derived from defined tumor-associated antigens.

30 vaccine strategies to enhance reactivity to tumor-associated antigens.

31 munoglobulin M (IgM), which is reactive with tumor-associated antigens.

32 both CD4(+) and CD8(+) T cells specific for tumor-associated antigens.

33 nes is of importance to immunization against tumor-associated antigens.

34 ab' fragments from antibodies that recognize tumor-associated antigens.

35 nses to cancer by stimulating the release of tumor-associated antigens.

36 sing patient T cells redirected to recognize tumor-associated antigens.

37 rgeted therapies, such as mAbs, that bind to tumor-associated antigens.

38 itoring of T-cell responses to microbial and tumor-associated antigens.

39 is also being evaluated to target non-viral tumor-associated antigens.

40 ic antigen receptors (CARs) directed against tumor-associated antigens.

41 nd IgE classes directed specifically against tumor-associated antigens.

42 fy antitumor immunity through the release of tumor-associated antigens.

43 variants endowed with enhanced affinity for tumor-associated antigens.

44 nking strategy applicable to many additional tumor-associated antigens.

45 nity directed toward tumors bearing distinct tumor-associated antigens.

46 ETAA1 (Ewing tumor-associated antigen 1), also known as ETAA16, was i

47 encoded a protein that was termed colorectal tumor-associated antigen-1 (COA-1).

48 ety of a monoclonal antibody recognizing the tumor-associated antigen 5T4.

49 mph nodes, where the processed and presented tumor-associated antigens activate tumor-specific naive

50 viral gene products are capable of acting as tumor-associated antigens activating both T-cell and B-c

51 lopment of CD8(+) T-cell responses targeting tumor-associated antigens after autologous stem cell tra

52 ard method exists for cloning the recognized tumor-associated antigen (Ag).

53 expressed Y-encoded minor H antigen or to a tumor-associated antigen, although poorly effective if i

54 es based on homology between anti-id mAb and tumor-associated antigen amino acid sequences.

55 ssed individual seroreactivity to meningioma tumor-associated antigens among participants enrolled in

56 ands, cationic W-TBP mediates PDT to release tumor associated antigens and delivers immunostimulatory

57 esis and progression, MUCL1 is an attractive tumor-associated antigen and a potential therapeutic tar

58 PRAME is a tumor-associated antigen and has been described as a cor

59 Fusion cells coexpressed tumor-associated antigens and DC-derived costimulatory m

60 carcinoma cells reverse unresponsiveness to tumor-associated antigens and induce the rejection of es

61 ortant in this context as they may recognize tumor-associated antigens and induce tumor regression.

62 to naturally occurring tumor peptides (both tumor-associated antigens and neoantigens), as well as t

63 Tumor-associated antigens and peptides, genes encoding t

64 u tumor vaccine, induce CD8+ T cells against tumor-associated antigens and provide a viable oncologic

65 dritic cells (DCs) are capable of presenting tumor-associated antigens and subsequently play an essen

66 lack of enough high-affinity T cells against tumor-associated antigens and the unpredictability of tu

67 e modulation of CD40 to reverse tolerance to tumor-associated antigens and the use of OX40 to enhance

68 potent antigen-presenting cells, to present tumor-associated antigens and thereby generate tumor-spe

69 y increase the immune response to autologous tumor-associated antigens and, thus, may elicit immune-m

70 e and elicit robust immune responses against tumor-associated antigens and/or neoantigens.

71 s compared with normal tissues; these "self" tumor-associated antigens are also expressed during feta

72 proven challenging, as the vast majority of tumor-associated antigens are also expressed in normal t

73 poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated

74 Many tumor-associated antigens are derived from nonmutated "s

75 show that CD8 T-cell responses to viral and tumor-associated antigens are greatly underestimated in

76 Many tumor-associated antigens are nonmutated, poorly immunog

77 derlying poor immune responses to autologous tumor-associated antigens are overwhelming tumor kinetic

78 s, like EBV-immortalized B cells, expressing tumor-associated antigens are potentially useful immunog

79 Small organic ligands, selective for tumor-associated antigens, are increasingly being consid

80 for a unique class of shared immunodominant tumor associated antigens as targets for antitumor immun

81 offers insight into the possible use of this tumor-associated antigen as a target for immunotherapy.

82 tain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant ant

83 The p53 molecule might serve as a common tumor-associated antigen, as the tumor suppressor gene p

84 vely, these findings provide a rationale for tumor-associated antigen-based immunization as a means o

85 specific for and associated with unknown 4T1 tumor-associated antigens, because rejection of mKSA did

86 , processing, and presentation of autologous tumor-associated antigens by APC with Fc receptors.

87 (sc) Fv phage library was used to search for tumor-associated antigens by panning with a lung adenoca

88 of HSV can be retargeted to cells expressing tumor-associated antigens by single-chain antibodies fus

89 Direct antigen presentation of tumor-associated antigens by tumor cells to T lymphocyte

90 gies which enhance immune activation against tumor-associated antigens can also be used to enhance th

91 Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specif

92 dies have demonstrated that vaccination with tumor-associated antigens can expand Tregs, posing a cha

93 TEX carrying tumor-associated antigens can interfere with antitumor i

94 tumor microenvironment, primed to recognize tumor-associated antigens, can occur in response to immu

95 hat expresses the targetable, membrane-bound tumor-associated antigen carbonic anhydrase type 9 (CA I

96 major mugwort pollen allergen Art v 1 and a tumor-associated antigen, carbonic anhydrase 9.

97 pressed single-domain antibody directed to a tumor-associated antigen (CD20).

98 noclonal antibody, RS-11, which recognizes a tumor-associated antigen common to several species.

99 Tumor-associated antigen cytotoxic T cells (TAA-Ts) repr

100 tric solid tumor with high expression of the tumor associated antigen disialoganglioside GD2.

101 TF-antigen is a tumor-associated antigen displayed on cell surface prote

102 gen spreading and a reduction in circulating tumor-associated antigen DNA levels in patients with rel

103 ic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and h

104 bulin-like proteins, which include the mouse tumor-associated antigen E4 (Tage4) and three proteins t

105 ifferentially recognizes various epitopes of tumor-associated antigens either as self or as foreign,

106 The tumor-associated antigen EpCAM (GA733-2) is a highly exp

107 T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) could be d

108 The identification of novel tumor-associated antigens, especially those shared among

109 d to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastom

110 opes derived from the MAGE-6 gene product; a tumor-associated antigen expressed by most melanomas and

111 Mesothelin is a cell-surface tumor-associated antigen expressed in several human canc

112 Telomerase reverse transcriptase (TRT) is a tumor-associated antigen expressed in the vast majority

113 Carcinoembryonic antigen (CEA) is a tumor-associated antigen expressed on most gastrointesti

114 To identify potentially relevant tumor-associated antigens expressed in renal cell carcin

115 procedure for generating mAbs reacting with tumor-associated antigens expressed on human prostate ca

116 .5) mAbs have been developed that react with tumor-associated antigens expressed on human prostate ca

117 several mechanisms: (a) increase in MHC and tumor-associated antigen expression by tumor cells; (b)

118 Several tumor-associated antigen families, such as MAGE, GAGE/PA

119 r cytotoxin/immunotoxin, or alternatively, a tumor-associated antigen for active, specific immunother

120 s, hedgehog-interacting protein (Hip1), as a tumor-associated antigen for immunoprevention of BCCs in

121 This suggests IL1RAP as a tumor-associated antigen for immunotherapy cell targetin

122 onstraints have led to a relative paucity of tumor-associated antigens for antibody targeting in onco

123 The ability to present tumor-associated antigens for both induction of antitumo

124 sferred epidermal cells were able to present tumor-associated antigens for in vivo anti-tumor immunit

125 nt a soluble extract of tumor as a source of tumor-associated antigens for the induction of in vivo a

126 f dermal antigen-presenting cells to present tumor-associated antigens for the induction of in vivo a

127 For example, Langerhans cells can present tumor-associated antigens for the induction of substanti

128 r novel methods of loading DCs with relevant tumor-associated antigens for vaccine development.

129 resent a wide variety of antigens, including tumor-associated antigens, for various immune responses.

130 fusion protein composed of an amino-terminal tumor-associated antigen fragment fused to the CD40 liga

131 thelial cell adhesion molecule (HEPCAM) is a tumor-associated antigen frequently expressed in carcino

132 ther to medium alone or to medium containing tumor-associated antigens from S1509a tumor cells.

133 also of T cells that are specific for known tumor-associated antigens from the endogenous immune rep

134 ha1-->2FucT, which are known to be important tumor-associated antigens (fucosyl-GM1 and fucosyl-Gb5),

135 oexpressing high levels of human TfR and the tumor-associated antigen gp40 by binding to both target

136 man transferrin receptor (TfR) and the human tumor-associated antigen gp40.

137 for spontaneous CD8+ T cell priming against tumor-associated antigens has generated renewed interest

138 Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugate

139 encies of T lymphocytes specific for certain tumor-associated antigens have been detected in some can

140 Recently, autoantibodies to tumor-associated antigens have been identified in cancer

141 Numerous tumor-associated antigens have been identified in melano

142 Human Tregs with specificity for tumor-associated antigens have recently been identified,

143 Autoantibodies raised against tumor-associated antigens have shown high promise as cli

144 c antigen receptor (CAR), which recognizes a tumor-associated antigen, have shown activity against he

145 vivo while down-regulating the expression of tumor-associated antigens important in eliciting CTL res

146 ed to be a useful method to detect tumor and tumor-associated antigens in a variety of malignancies.

147 The immunogenicity of tumor-associated antigens in autologous tumor vaccines i

148 However, like most tumor-associated antigens in immunocompetent hosts, thes

149 92, a human NK cell line, may be targeted to tumor-associated antigens in solid malignancies where it

150 Several tumor-associated antigens in tumor cells have been ident

151 ARs) to redirect their specificity to target tumor-associated antigens in vivo.

152 eted expansion of autologous T cells against tumor-associated antigens, including prostate-specific m

153 s were directed against a broad set of renal tumor-associated antigens, including telomerase reverse

154 iation therapy can enhance the expression of tumor-associated antigens, induce immune-mediated target

155 these experiments, dermal cells pulsed with tumor-associated antigens induced protective immunity to

156 eptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2

157 The role, if any, of immunity to this tumor-associated antigen is not known.

158 emonstrate that unresponsiveness to the MUC1 tumor-associated antigen is reversible by immunization w

159 sfer of T-cell receptors (TCRs) specific for tumor-associated antigens is a promising approach for ca

160 ed intracerebral immunity against endogenous tumor-associated antigens is dependent on both CD4(+) an

161 sgenic plants that recognizes the nonprotein tumor-associated antigen Lewis Y oligosaccharide overexp

162 antigen receptor directed against a specific tumor-associated antigen like CD19 in lymphoma.

163 alyses showed that T cells reactive with the tumor-associated antigen LMP2 were present in the infuse

164 The vector-mediated in vivo activation, and tumor-associated antigen loading of dendritic cells does

165 pecific T-cell clones against one or more of tumor-associated antigens MAGE-1, gp100, and HER-2 after

166 >4-N-acetylgalactosaminyl-transferase, and a tumor-associated antigen (MAGE-A3).

167 ) optimization to enhance affinity against a tumor-associated antigen, MAGE-A3.

168 transferred CD8+ T cell clones targeting the tumor-associated antigens, MART1MelanA and gp100 for the

169 Promoters for tumor-associated antigens may be incorporated into the H

170 ified by recombinant adenoviruses expressing tumor-associated antigens may provide an effective antit

171 neoplastic agents to antibodies specific for tumor-associated antigens may represent a novel platform

172 Specific immune responses to tumor-associated antigens might correlate with disease-f

173 Clinically, the exploitation of tumor-associated antigen mimics may contribute to the de

174 n immunogenic, low-affinity peptide from the tumor-associated antigen MUC1, bound to H-2Kb.

175 aturally occurring antibody responses to the tumor-associated antigen mucin 1 (MUC1), but the host ge

176 velopment for other human cancers, for which tumor-associated antigens need not be defined.

177 re simultaneously the immune reactivity to a tumor-associated antigen, neu, and an unrelated self-ant

178 Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either f

179 Immunoediting of tumor-associated antigens occurs in response to immune p

180 This requires indirect presentation of tumor-associated antigens on surrounding antigen-present

181 t secondary CD8 T-cell response specific for tumor-associated antigens other than WT1.

182 GD3 is a tumor-associated antigen otherwise found in melanoma and

183 Mucin 1 (MUC1) glycoprotein is a tumor-associated antigen overexpressed in ovarian cancer

184 erived from tumor-bearing patients recognize tumor-associated antigens presented by major histocompat

185 ich can eradicate tumor cells by recognizing tumor-associated antigens presented by MHC class I molec

186 in situ so that the cancer cells can act as tumor-associated antigen-presenting cells (tAPCs) by ind

187 ts establish that cps preferentially invades tumor-associated antigen-presenting cells and restores t

188 It encodes 2 tumor-associated antigens, prostate-specific antigen (PS

189 ces cerevisiae (yeast) capable of expressing tumor-associated antigen protein.

190 capromab pendetide depends on expression of tumor-associated antigen rather than lesion size.

191 may be caused by exaggerated suppression of tumor-associated antigen-reactive lymphocytes mediated b

192 g cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like o

193 Methodology for identifying tumor-associated antigens recognized by T cells has been

194 Many tumors overexpress tumor-associated antigens relative to normal tissue, suc

195 o mediate effective vaccination against weak tumor-associated antigens remain unclear.

196 ting either MHC class I or II neoantigens or tumor-associated antigens rendered up to 60% of the tota

197 Most tumor-associated antigens represent self-proteins and as

198 isteria DeltaactA/DeltainlB expressing human tumor-associated antigens represents an attractive thera

199 proliferation of CD8(+) T cells specific to tumor-associated antigens, resulting in cancer-specific

200 g lymphodepletion, CAR-T cells targeting the tumor-associated antigen ROR1 lysed tumors in mice but i

201 he use of whole tumor lysates as a source of tumor-associated antigen(s) for pulsing of DC circumvent

202 inhibitor, that can, without using exogenous tumor-associated antigen(s), eliminate various large tum

203 s macrophage-derived dendritic cells induced tumor-associated antigen-specific CD8+ T cells with effe

204 sed and characterized functional recombinant tumor-associated antigen-specific chimeric IgE/kappa and

205 pressing cells and reversal of inhibition to tumor-associated antigen-specific CTL generation in vitr

206 tly suppress myeloid dendritic cell-mediated tumor-associated antigen-specific T cell effector functi

207 ut not primary ovarian tumor cells, suppress tumor-associated antigen-specific T cell immunity.

208 + regulatory T cells (Treg cells) suppressed tumor-associated antigen-specific T-cell immunity.

209 n vivo expansion of transgenic T cells after tumor-associated antigen stimulation.

210 g in patients with tumors expressing defined tumor-associated antigens such as MAGE-1.

211 e target for CAR therapy or be combined with tumor-associated antigens such as melanoma cell adhesion

212 malignant glioma cells express certain known tumor-associated antigens, such as HER-2, gp100, and MAG

213 antibodies recognizing MCPyV large and small tumor-associated antigens (T-Ag) would be more specifica

214 Immune complexes (IC) containing the tumor-associated antigen TA90 can be identified in the s

215 ad, CA) induces antibodies to a glycoprotein tumor-associated antigen (TA90).

216 receptor (CAR) to redirect specificity to a tumor associated antigen (TAA) thereby conferring antitu

217 fixed antigen specificity such that only one tumor-associated antigen (TAA) can be targeted, limiting

218 s potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitu

219 tients with advanced melanoma that is of low tumor-associated antigen (TAA) expression often respond

220 The use of tumor-associated antigen (TAA) mRNA for therapeutic purp

221 DC pulsed with tumor-associated antigen (TAA) peptide or protein have r

222 When pulsed with tumor-associated antigen (TAA) peptide or protein, murin

223 Survivin is a tumor-associated antigen (TAA) that inhibits apoptosis a

224 (MART-1) antigen system as a prototype human tumor-associated antigen (TAA)- and dendritic cell (DC)-

225 The presence of tumor-associated antigen (TAA)-specific CD8(+) T cell po

226 ession of PD-1, TIM3, and LAG3 was higher on tumor-associated antigen (TAA)-specific CD8(+) TIL, comp

227 Retention of human herpes virus and tumor-associated antigen (TAA)-specific immunity was mea

228 ing the anergy that exists in tumor hosts to tumor-associated antigen (TAA).

229 strategy to identify breast cancer antigens [tumor-associated antigen (TAA)].

230 Recombinant poxviruses encoding tumor-associated antigens (TAA) are attractive as candid

231 Vaccines based on tumor-associated antigens (TAA) have limited therapeutic

232 The discovery of tumor-associated antigens (TAA) in certain human maligna

233 The identification of new tumor-associated antigens (TAA) is critical for the deve

234 yanin and MHC-I alone or MHC-I/II-restricted tumor-associated antigens (TAA) of tyrosinase and gp100,

235 Therapeutic subunit vaccines based on tumor-associated antigens (TAA) represent an attractive

236 e vectors may not be effective at presenting tumor-associated antigens (TAA) to the immune system in

237 Most cancer vaccines induce CTL responses to tumor-associated antigens (TAA).

238 ng CD8(+) T-cell responses targeting several tumor-associated antigens (TAA).

239 r inducing clinical regressions by targeting tumor-associated antigens (TAA).

240 Subunit vaccines containing universal tumor associated antigens (TAAs) present an attractive t

241 a panel of 10 proteins, including well-known tumor-associated antigens (TAAs) and potential new bioma

242 ful method for serological identification of tumor-associated antigens (TAAs) and/or tumor rejection

243 Tumor-associated antigens (TAAs) are monomorphic self-an

244 influenza virus vectors expressing selected tumor-associated antigens (TAAs) as therapeutic agents i

245 ) and chimeric antigen receptors recognizing tumor-associated antigens (TAAs) can now be engineered t

246 cer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting st

247 apeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism

248 ing CD8+ T-cell populations specific for the tumor-associated antigens (TAAs) MART-1 (27-35) or tyros

249 uggest that immunotherapy targeting specific tumor-associated antigens (TAAs) may be beneficial in ca

250 Donor-derived immunity against tumor-associated antigens (TAAs) may exert selective ant

251 cyte responses against multiple epitopes and tumor-associated antigens (TAAs) may provide effective i

252 Characterization of tumor-associated antigens (TAAs) recognized by CTLs make

253 se expression of tumor-specific antigens and tumor-associated antigens (TAAs) that can activate antit

254 lls serve as the superior source of multiple tumor-associated antigens (TAAs) to pulse dendritic cell

255 Autoantibodies directed against tumor-associated antigens (TAAs) were shown to be releva

256 gies to enhance immune responses to specific tumor-associated antigens (TAAs), including the increasi

257 late proliferation of T cells that recognize tumor-associated antigens (TAAs), this expansion does no

258 Patients can generate antibodies to tumor-associated antigens (TAAs).

259 mplantation of the second EVA rods releasing tumor-associated antigens (TAAs).

260 Carcinoembryonic antigen (CEA) is a tumor-associated antigen targeted for the development of

261 This report describes a tumor-associated antigen, termed CML66, initially cloned

262 The MN/CA9 protein is a tumor-associated antigen that has been shown to have dia

263 e normal tissues by specifically targeting a tumor-associated antigen that is also expressed on those

264 ancer is overcoming immunologic tolerance to tumor-associated antigens that are expressed on both mal

265 A large number of human tumor-associated antigens that are recognized by CD8(+)

266 Thus, MICA/B are tumor-associated antigens that can be recognized, in an

267 reatment-induced suppression nor tolerant to tumor-associated antigens that have been encountered in

268 tumor cells can enable T-cell recognition of tumor-associated antigens that were previously silent wh

269 CD8+ and CD4+ T-cell responses against a new tumor-associated antigen, the receptor tyrosine kinase E

270 The release of tumor-associated antigens then promotes the maturation o

271 Even if neoplastic cells express tumor associated antigens they still may fail to functio

272 g to additional T cell responses to nonviral tumor-associated antigens through epitope spreading.

273 The new vaccine contains prostate tumor-associated antigens, Tn, TF, STn, Lewis(y), and Gl

274 monoclonal antibody (MAb) that recognizes a tumor-associated antigen to image the fluorescence emitt

275 aboratory has established that the fusion of tumor-associated antigens to a truncated form of the Lis

276 tic cells and enhanced cross-presentation of tumor-associated antigens to CD8 T cells.

277 apoptotic tumor cells (ATCs) and presenting tumor-associated antigens to immune cells.

278 ich simultaneously target CD3 on T cells and tumor-associated antigens to recruit cytotoxic T cells t

279 s resulted in enhanced cross-presentation of tumor-associated antigens to specific T cells in vitro.

280 les of neutrophils and B cells in presenting tumor-associated antigens to T cells in this combination

281 The process through which tumor-associated antigens trigger humoral response is no

282 ide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases s

283 gen spreading and a reduction in circulating tumor-associated antigens using digital droplet polymera

284 on augments the host immune response against tumor-associated antigens via delivery of immune stimula

285 noclonal antibody raised against the 250 kDa tumor associated antigen was reached by using only seven

286 Similarly, the promoter for the DF3/MUC1 tumor-associated antigen was cloned into a third HSV-1 m

287 uman model for eliciting T-cell responses to tumor-associated antigens, we develop a novel strategy t

288 b to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity

289 Dermal cells exposed to tumor-associated antigens were also able to elicit delay

290 carcinoembryonic antigen (CEA) and MUC1/DF3 tumor-associated antigens were characterized and cloned

291 nd cytotoxicity against autologous tumor and tumor-associated antigens were measured.

292 ) cells express idiotypic proteins and other tumor-associated antigens which make them ideal targets

293 mbryonic antigen (CEA) is an important self, tumor-associated antigen, which is expressed by differen

294 ntation of a broad repertoire of (undefined) tumor-associated antigens, which reduces emergence of tr

295 variable fragment (Fv) from an antibody to a tumor-associated antigen with a 38-kDa fragment of PE (P

296 ognizing a naturally processed and presented tumor-associated antigen with a chimeric PD-1:28 recepto

297 ion of human epitope-specific CTLs against a tumor-associated antigen with a live attenuated recombin

298 Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular

299 e T cells with ability to directly recognize tumor-associated antigens without the need for presentat

300 utated oncogenic growth factor receptors, as tumor-associated antigens yields rational targets for sp